181 related articles for article (PubMed ID: 27749663)
41. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.
Cascio A; Gradoni L; Scarlata F; Gramiccia M; Giordano S; Russo R; Scalone A; Camma C; Titone L
Am J Trop Med Hyg; 1997 Jul; 57(1):75-8. PubMed ID: 9242323
[TBL] [Abstract][Full Text] [Related]
42. [Emergent outbreak of visceral leishmaniasis in Mato Grosso do Sul State].
Oliveira AL; Paniago AM; Dorval ME; Oshiro ET; Leal CR; Sanches M; Cunha RV; Bóia MN
Rev Soc Bras Med Trop; 2006; 39(5):446-50. PubMed ID: 17160321
[TBL] [Abstract][Full Text] [Related]
43. [Demographic, clinical and therapeutic features of adult visceral leishmaniasis at the Rabta hospital in Tunis (tunisia) from 1983 to 2002].
Toumi A; Kilani B; Ammari L; Tiouiri H; Kanoun F; Belhadj S; Chaker E; Ben Chaabene T
Bull Soc Pathol Exot; 2007 Oct; 100(4):282-6. PubMed ID: 17982860
[TBL] [Abstract][Full Text] [Related]
44. [The first case of visceral leishmaniasis in a patient with HIV infection in Russia].
Ermak TN; Kravchenko AV; Gruzdev BM; Filippov PG
Ter Arkh; 1997; 69(11):48-50. PubMed ID: 9483748
[TBL] [Abstract][Full Text] [Related]
45. Clinical characteristics and spatial distribution of Visceral leishmaniasis in children in São Paulo state: an emerging focus of Visceral leishmaniasis in Brazil.
Naufal Spir PR; Prestes-Carneiro LE; Fonseca ES; Dayse A; Giuffrida R; D'Andrea LA
Pathog Glob Health; 2017 Mar; 111(2):91-97. PubMed ID: 28221822
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
47. [Evaluation of fourteen adult cases with visceral leishmaniasis].
Kurşun E; Turunç T; Demiroğlu YZ; Solmaz S; Arslan H
Mikrobiyol Bul; 2013 Jul; 47(3):500-6. PubMed ID: 23971927
[TBL] [Abstract][Full Text] [Related]
48. [Case report: the efficacy of amphotericin B in visceral leishmaniasis].
Güleç SG; Kizilyer Y; Karaman S; Erdem E; Urganci N
Turkiye Parazitol Derg; 2010; 34(2):73-5. PubMed ID: 20597048
[TBL] [Abstract][Full Text] [Related]
49. [Misleading forms of visceral leishmaniasis in children. Apropos of 5 cases].
Ben Becher S; Zaafouri M; Ghram N; Hammami E; Khiari S; Boudhina T
Med Trop (Mars); 1991; 51(3):289-92. PubMed ID: 1943639
[TBL] [Abstract][Full Text] [Related]
50. Visceral leishmaniasis: a common cause of post-infectious febrile pancytopenia in children in an endemic area: experience of a children's tertiary hospital.
Alexandropoulou O; Tsolia M; Kossiva L; Giannaki M; Karavanaki K
Pediatr Emerg Care; 2012 Jun; 28(6):533-7. PubMed ID: 22653455
[TBL] [Abstract][Full Text] [Related]
51. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
Shahian M; Alborzi A
Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
[TBL] [Abstract][Full Text] [Related]
52. Visceral leishmaniasis: A leucaemia mimicker: A case report.
Rathod SG; Chozakade A; Akhoon T; Jalid A; Roshan R
Trop Doct; 2022 Oct; 52(4):586-587. PubMed ID: 35880300
[TBL] [Abstract][Full Text] [Related]
53. Pediatric Visceral Leishmaniasis Caused by Leishmania infantum in Northern Cyprus.
Sayili A; Ozkan AT; Schallig HD
Am J Trop Med Hyg; 2016 Dec; 95(6):1386-1388. PubMed ID: 27698271
[TBL] [Abstract][Full Text] [Related]
54. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
55. [An adult case of visceral leishmaniasis in a province of Black-Sea region, Turkey].
Oztoprak N; Aydemir H; Pişkin N; Seremet Keskin A; Araslı M; Gökmen A; Celebi G; Külekçi Uğur A; Taylan Özkan A
Mikrobiyol Bul; 2010 Oct; 44(4):671-7. PubMed ID: 21063981
[TBL] [Abstract][Full Text] [Related]
56. [Visceral leishmaniasis. Personal observation and review of epidemiology, clinical aspects and therapy].
Dickerhoff R; Müller A; Bode U
Klin Padiatr; 1990; 202(5):347-51. PubMed ID: 2170739
[TBL] [Abstract][Full Text] [Related]
57. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
[TBL] [Abstract][Full Text] [Related]
58. Hemophagocytic syndrome: A misleading complication of visceral leishmaniasis in children--a series of 12 cases.
Gagnaire MH; Galambrun C; Stéphan JL
Pediatrics; 2000 Oct; 106(4):E58. PubMed ID: 11015553
[TBL] [Abstract][Full Text] [Related]
59. Kala-azar in Afghanistan.
Singh M; Arya LS; Aram GN; Fazal MI; Qureshi MA; Goel RG
J Trop Med Hyg; 1982 Oct; 85(5):201-4. PubMed ID: 7176002
[TBL] [Abstract][Full Text] [Related]
60. Splenic granulomatous lesions in immunocompetent pediatric patients with visceral leishmaniasis.
Fretzayas A; Moustaki M; Kitsiou S; Mathioudakis J; Karpathios T
Scand J Infect Dis; 2001; 33(11):865-7. PubMed ID: 11760174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
